In a patient with severe hypertension presenting with dysarthria and right‑hand weakness that resolved within 30–40 minutes after rapid blood‑pressure reduction with hydralazine, what is the most likely explanation?

Cerebral Hypoperfusion from Excessive Blood Pressure Reduction

This patient most likely experienced cerebral hypoperfusion (watershed ischemia) due to excessively rapid blood pressure reduction with hydralazine, causing transient ischemic symptoms that resolved when cerebral perfusion was restored.

Mechanism and Clinical Context

The clinical sequence is highly characteristic of iatrogenic cerebral hypoperfusion:

• Initial presentation: Hypertensive urgency (BP 200/110) with dysarthria but negative CT—suggesting either a transient ischemic attack or symptoms from severe hypertension itself
• Critical error: Hydralazine caused precipitous BP drop from 200/110 to 140/80 (mean arterial pressure reduction of approximately 33%)
• Consequence: New focal neurological deficits (dysarthria and right-sided weakness) appeared after BP reduction, lasting 30-40 minutes before spontaneous resolution

This pattern indicates the brain was dependent on elevated perfusion pressure, and rapid normalization caused watershed zone ischemia that reversed when autoregulation compensated.

Why This Represents Guideline Violation

Current ESC guidelines explicitly warn against this scenario 1, 2:

• Hypertensive urgency (severe hypertension without acute organ damage) should have BP reduced gradually over 24-48 hours, not acutely 1
• Even in hypertensive emergencies with stroke, BP reduction should be controlled and limited to 15-20% MAP reduction 1
• Rapid BP lowering is contraindicated as it can lead to cardiovascular and cerebrovascular complications 1

The 2024 ESC guidelines reinforce that patients with chronically elevated BP have altered cerebral autoregulation curves—acute normalization causes hypoperfusion in these patients 2.

Hydralazine-Specific Concerns

The FDA label for hydralazine specifically cautions: "It should be used with caution in patients with cerebral vascular accidents" 3. The drug causes:

• Unpredictable BP responses
• Reflex tachycardia and increased cardiac output 3
• Potential for excessive drops, particularly problematic in cerebrovascular disease 3

Recent evidence confirms hydralazine combinations carry highest odds of over-reduction (mOR: 3.04) 4, and its use in asymptomatic elevated BP is increasingly recognized as inappropriate 5.

Clinical Pitfalls to Avoid

Key errors in this case:

1. Treating hypertensive urgency as an emergency: No acute organ damage was present initially (negative CT), yet IV medication was used
2. Excessive magnitude of reduction: 33% MAP reduction far exceeds the 15-20% recommended even for emergencies 1
3. Wrong drug selection: Hydralazine is not first-line for any hypertensive scenario; labetalol or nicardipine are preferred 1, 2
4. Too rapid reduction: Should occur over hours to days, not minutes 1, 6

The transient nature of symptoms (30-40 minutes) supports reversible ischemia rather than completed stroke—consistent with temporary hypoperfusion until compensatory mechanisms restored adequate cerebral blood flow.

Correct Management Approach

For similar presentations:

• Hypertensive urgency: Oral agents (captopril, labetalol) with gradual reduction over 24-48 hours 1, 4
• If stroke suspected: Withhold BP lowering unless >220/120 mmHg, then reduce by only 15% over 1 hour 1
• Avoid: Hydralazine, immediate-release nifedipine, and any rapid-acting agents in non-emergency settings 7, 8
• Monitor: For new neurological symptoms during any BP reduction, which should prompt immediate cessation

The development of new focal deficits after BP treatment is a red flag for iatrogenic hypoperfusion and represents a preventable complication of overly aggressive management.